Today is the first day of trading in
"We are very happy for the interest in Ectin that the issue of shares has shown. The IPO process has made Ectin visible on the market and given new shareholders the possibility to join and share our ambition to establish MFA-370 as the first oral treatment for metastatic urothelial bladder cancer with few and tolerable potential side effects. The capital makes it now financially possible for us to initiate the planned phase I/II study during H2 2021," says, CEO, Anna Sjöblom-Hallén.
"Today, trading begins in
Press contact
+46 79 006 65 66, ae@spotlightstockmarket.com
ABOUT SPOTLIGHT
Spotlight is the marketplace where investors and growth companies meet. At Spotlight, it is easier and safer for companies to be listed. We offer an overall solution that increases the visibility of our companies through unique media collaborations. Investors get through Spotlight the opportunity to become shareholders in approximately 160 growth companies from different businesses and countries, among those are
spotlightstockmarket.com
https://news.cision.com/spotlight-stock-market/r/first-day-of-trading-in-ectin-research,c3398956
https://mb.cision.com/Main/9351/3398956/1455646.pdf
https://news.cision.com/spotlight-stock-market/i/img-1143-2,c2944836
(c) 2021 Cision. All rights reserved., source